伴同性动物药物市场规模、份额和成长分析（按伴同性动物、药物类别、分销管道和地区）- 产业预测 2025-2032

伴同性动物药物市场规模预计将在 2023 年达到 158 亿美元，从 2024 年的 168.7 亿美元增长到 2032 年的 285.6 亿美元，在预测期内（2025-2032 年）的复合年增长率为 6.8%。

受宠物拥有量激增、宠物保健意识增强和动物用药品进步的推动，全球伴同性动物药物市场正在蓬勃发展。随着越来越多的家庭饲养宠物，对狗、猫和其他动物的药物和治疗的需求不断增长。主要成长动力包括更重视预防性医疗保健，包括接种疫苗和驱虫，以及多样化的慢性病治疗方案。此外，药物传输系统的创新，例如调味锭剂和外用製剂，正在改善饲主的药物管理。随着宠物健康成为首要任务，市场区隔将持续成长，为製药公司和兽医进入这个不断扩大的市场提供了宝贵的机会。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析

伴同性动物药物市场规模（以伴同性动物划分）

• 市场概况
• 狗
• 猫
• 马
• 其他的

伴同性动物药物市场规模（依药物类别划分）

• 市场概况
• 抗生素
• 消炎（药
• 心丝虫药
• 杀寄生虫剂
• 营养药物
• 行为药物
• 疫苗
• 其他的

伴同性动物药物市场规模（依分销管道划分）

• 市场概况
• 兽医药房
• 电子商务
• 零售药局

伴同性动物药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Zoetis（USA）
• Elanco Animal Health（USA）
• Virbac（France）
• Ceva Sante Animale（France）
• Boehringer Ingelheim（Germany）
• Merck Animal Health（USA）
• Bayer Animal Health（Germany）
• Kemin Industries（USA）
• Hester Biosciences（India）
• Vetoquinol（France）
• Dechra Pharmaceuticals（UK）
• IDEXX Laboratories（USA）
• Mars Petcare（USA）
• Nestle Purina Petcare（Switzerland）
• Hill's Pet Nutrition（USA）
• Boehringer Ingelheim Vetmedica（Germany）
• MSD Animal Health（USA）
• Bayer HealthCare Animal Health（Germany）
• Virbac Animal Health（France）
• Ceva Animal Health（France）

结论和建议

Companion Animal Drugs Market size was valued at USD 15.8 billion in 2023 and is poised to grow from USD 16.87 billion in 2024 to USD 28.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global companion animal drugs market is thriving, fueled by the surge in pet ownership, increased awareness of pet healthcare, and advancements in veterinary pharmaceuticals. As more households adopt pets, the demand for medications and treatments for dogs, cats, and other animals continues to rise. Key growth drivers include a heightened emphasis on preventive care-encompassing vaccinations and parasite control-and a diverse range of therapeutic solutions for chronic conditions. Furthermore, innovation in drug formulations and delivery systems, such as flavored tablets and topical applications, has improved medication administration for pet owners. With the ongoing prioritization of pet well-being, the companion animal drugs market is poised for sustained growth, presenting valuable opportunities for pharmaceutical companies and veterinarians to engage this expanding segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Companion Animal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Companion Animal Drugs Market Segments Analysis

Global Companion Animal Drugs Market is segmented by Companion Animals, Drug Class, Distribution Channel and region. Based on Companion Animals, the market is segmented into Dogs, Cats, Horses and Others. Based on Drug Class, the market is segmented into Antibiotics, Anti-inflammatory, Heart Worm Drugs,parasiticides, Nutritional Drugs, Behavioral Drugs, Vaccines and Others. Based on Distribution Channel, the market is segmented into Veterinary Pharmacies, E-commerce and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Companion Animal Drugs Market

The Companion Animal Drugs market is experiencing significant growth driven by advancements in veterinary medicine. These enhancements encompass the creation of more effective diagnostics, treatments, and pharmaceuticals. As a result, the variety of treatment options available is expanding, leading to improved disease management and higher efficacy in therapy. This progress has heightened the demand for advanced medications for companion animals, reflecting a growing recognition of the importance of pet health and well-being. Consequently, the overall landscape of the companion animal drug market is evolving, creating opportunities for innovative solutions to address the medical needs of pets.

Restraints in the Companion Animal Drugs Market

The Companion Animal Drugs market is encountering significant challenges due to the financial strain associated with these medications and treatments. Many consumers are hesitant to invest in their pets' health because of the high costs involved, which can delay or obstruct market adoption. Pet owners, particularly those in low-income areas or with limited budgets, often perceive the prices of these healthcare options as prohibitively expensive. This can deter them from seeking necessary treatments and medications for their pets, ultimately impacting the growth and accessibility of the market for companion animal healthcare solutions.

Market Trends of the Companion Animal Drugs Market

The Companion Animal Drugs market is experiencing a significant trend towards digital health solutions, driven by the integration of advanced data analytics, telehealth services, wearable devices, and mobile applications. This technological shift enables pet owners to remotely monitor their animals' health indicators, fostering better communication with veterinarians and enhancing overall healthcare management. With these innovations, pet owners can efficiently manage medicinal prescriptions and adhere to treatment protocols, ultimately improving pet welfare and satisfaction. As the market continues to embrace these digital solutions, the demand for companion animal drugs is likely to increase, reflecting a broader trend towards personalized and proactive veterinary care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Companion Animal Drugs Market Size by Companion Animals & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Horses
• Others

Global Companion Animal Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibiotics
• Anti-inflammatory
• Heart Worm Drugs
• Parasiticides
• Nutritional Drugs
• Behavioral Drugs
• Vaccines
• Others

Global Companion Animal Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Veterinary Pharmacies
• E-commerce
• Retail Pharmacies

Global Companion Animal Drugs Market Size & CAGR (2025-2032)

• North America (Companion Animals, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Companion Animals, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Companion Animals, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Companion Animals, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Companion Animals, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Animal Health (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mars Petcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Purina Petcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hill's Pet Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Vetmedica (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer HealthCare Animal Health (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac Animal Health (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Animal Health (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations